|
|
- 2019
Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two casesKeywords: disease-modifying therapy, fingolimod, multiple sclerosis, ocrelizumab, rebound Abstract: Fingolimod (FTY), an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound of disease activity after cessation of therapy
|
